A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).

Authors: Paul D. Nathan, Anna Maria Di Giacomo, Josep M. Piulats, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Karen Tonge, Lars Anders van der Veen, Michael M. F. Lahn

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9613

Source: Full article

---

Abstract

TPS9613